EdiGene raises $62M to expand gene editing technologies
Biotech company EdiGene has raised $62 million in financing to expand its genome editing technologies and to accelerate drug discovery and therapies. Read More
Agathos Biologics launches as a cell and gene therapy company
Agathos Biologics has launched as a cell and gene therapy research and development company in Fargo, ND. Read More
Precision NanoSystems launches T-cell kits for mRNA-lipid nanoparticles
Precision NanoSystems has launched its GenVoy-ILM T Cell Kit for messenger RNA (mRNA) to enable lipid nanoparticle-based ex vivo gene transfer. Read More
Sorrento reports positive clinical results for COVID-19 stem cell treatment
Sorrento said that all 10 of the COVID-19 patients receiving its stem cell treatment in a phase IB study were discharged from the intensive care unit within three days after their last infusion. Read More
Vertex, CRISPR Therapeutics ink deal on sickle cell gene therapy
Vertex Pharmaceuticals and CRISPR Therapeutics have amended their collaboration agreement to develop, manufacture, and commercialize CTX001, an ex vivo CRISPR/Cas9-based gene editing therapy being developed for the treatment of sickle cell disease and transfusion-dependent beta-thalassemia. Read More
Halo Labs launches Aura CL for cell therapy quality analysis
Halo Labs has launched Aura CL, a next-generation instrument to measure cell therapy product quality. Read More
Code Biotherapeutics launches to develop nonviral-based gene therapies
Code Biotherapeutics has launched with $10 million in financing and will focus on next-generation nonviral gene therapies. Read More
Lineage, Immunomic to develop glioblastoma immunotherapy
Lineage Cell Therapeutics and Immunomic Therapeutics have signed a worldwide license and development collaboration agreement to generate a novel candidate derived from Lineage's VAC allogeneic cancer immunotherapy platform, which targets a proprietary, tumor-associated antigen construct provided by Immunomic for the treatment of glioblastoma multiforme. Read More
Variant-resistant COVID-19 vaccines could be effective, cheap to make
Researchers have collaborated to create a new COVID-19 vaccine platform containing antigens against the fusion protein of the SARS-CoV-2 virus that could be effective against variants of the virus. The research was published online on April 15 in the Proceedings of the National Academy of Sciences. Read More
UC Davis to ship GemPharmatech mouse models in U.S.
GemPharmatech and the University of California, Davis (UC Davis) have entered into a service agreement for the UC Davis Mouse Biology Program to provide services to reanimate, cryopreserve, and ship live mice to GemPharmatech customers in the U.S. Read More
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter